60 people Geneva-based

2. OUR MISSIONTo reduce the burden of malaria in disease-endemic countriesby discovering, developing and facilitating access of new, effective and affordable anti-malaria medicines.  300 partners Africa 67 Americas 89 Asia-Oceania 70 Europe 79 37 projects In pipeline Research 21 Translational 9 Phase IIB/III 5 4 products launched >210 million people treated 60 people Geneva-based

4. Syndicated investmentProjected funding: 1999 to 2017

5. Leveraging donor funds PHARM A Pharma ‘in-kind’ ‘IN-KIN D ’ T O T AL MMV + = total MMV $1.00 + = £1.50 $1.50 $2.50 £1.00 Leveraging donor funds Pharma ‘co-funding’ £3.50 £1.00

6. Network of partners/assays MMV has assembled a network of partners/assays to select molecules with required properties P. yoelii/bergheiliver stage assay GNF Novartis/ UCSD, USA P. cynomolgihypnozoiteassayBPRC, Netherlands In vitro blood stage activity Swiss TPH, Switzerland & Eskitis, Australia Gametocycte and gamete formation assays Griffith University Australia and Imperial College UK Parasite Reduction Rate in vivohu-SCID model GSK TresCantos, Spain Gametocycteassay GSK TresCantos, Spain Membrane feed assay Imperial College, UK Resistance risk assessment Columbia University, USA Membrane feed assay TropIQ, Netherlands GSK, Tres Cantos A Liver-stage schizonts B Blood-stage schizonts C Gametocytes D Micro- and Macro-gametes/zygotes E Ookinetes F Oocysts G Sporozoites TCP1 TCP2 TCP3a TCP3b TCP4 Academia● Industry●

7. MMV–partnership pipeline Q1 2014

8. Before GLP preclinical GLP preclinical Phase I Phase II Phase III Launched Active 34 5 1 4 2 4 42 9 4 3 2 Terminated Focusing resources through early project prioritisation

9. INDUSTRY $180 MILLION Industry estimates for clinical development of an anti-infective (Tufts) 70% REDUCTION MMV $54 MILLION* Total clinical development costs for pyronaridine-artesunate Reducing costs in clinical development * Includes direct internal project costs, CRO costs and MMV management & administration costs.

10. INITIAL COST PROPOSAL Reducing partner & vendor costs e.g. non-clinical toxicology study

11. INITIAL COST PROPOSAL 73% REDUCTION CRO BID Reducing partner & vendor costs e.g. non-clinical toxicology study

12. INITIAL COST PROPOSAL 50% OF CRO BID 13% OF INITIAL PROPOSAL CRO BID MMV SHARE Reducing partner & vendor costs e.g. non-clinical toxicology study

13. ACT Terms of MMV alliance agreements 47% REDUCTION + Obligation to launch in malaria-endemic countries + Price targets & cost audits Access and affordability

14. UK 23 pence* to treat one child * cost for one 3-day course of Coartem-dispersible (Novartis public sector price for malaria-endemic countries; weighted average treatment regimen 2012; March 1st 2013 exchange rate)

15. >212 million treatments delivered and counting

16. CoartemDispersible 60-87 million children cured 200 million treatment courses delivered * estimates based upon drug distribution data, epidemiology / testing data and clinical efficacy data (PCR-corrected 28-day cure rate for Coartem Dispersible)

17. Impact beyond malaria

18. Providing researchers with 400 anti-malaria compounds to further R&D in other NTDs

19. 3 chemical series Providing researchers with 400 anti-malaria compounds to further R&D in other NTDs

20. 2 tropical diseases Sleeping sickness Leishmaniasis Providing researchers with 400 anti-malaria compounds to further R&D in other NTDs

21. MMV isgrateful for the financial support from the followingorganizations: